
Home » Spark Biomedical’s Opioid Withdrawal Treatment Earns FDA OK
Spark Biomedical’s Opioid Withdrawal Treatment Earns FDA OK

January 11, 2021
The FDA has granted 510(k) marketing clearance for Spark Biomedical’s Sparrow Therapy system, a wearable neurostimulator for treating opioid withdrawal.
The system, which is designed to be worn up to 24 hours a day during detoxification, stimulates nerves on and around the ear to help reduce withdrawal symptoms.
The Sparrow system is “the first clinically proven, drug-free, needle-free, wearable neurostimulation solution for opioid withdrawal relief,” offering an alternative to treatments that use drugs or acupuncture, Spark said.
Upcoming Events
-
26Jan
-
27Jan
-
27Jan
-
09Feb
-
10Feb
-
11Feb